# Vaxart to Participate in BTIG Infectious Disease Day 2026
Canonical URL: https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-infectious-disease-day-2026-65d0d8a3
Ticker: VXRT
Company: Vaxart
Source: Vaxart
Published: 2026-06-09 12:00 EST
## Summary

Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of...

## Article Body
Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in the BTIG Infectious Disease Day 2026 on June 16.

BTIG Infectious Disease Day 2026 Date: Tuesday, June 16, 2026 Format: 1x1 Meetings Location: Virtual

Institutional Investors interested in meeting with Vaxart management should contact their BTIG representative.

About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact Vaxart Media and Investor Relations: FINN Partners IR@vaxart.com
## Recent Company News
- 2026-07-21 12:00 EST — [Vaxart to Participate in BTIG Biotechnology Conference 2026](https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-biotechnology-conference-2026-f2702b19) — Source: Vaxart
- 2026-07-17 20:05 EST — [Vaxart Announces Results of Annual Meeting of Stockholders](https://biopharmsignal.com/news/VXRT/vaxart-announces-results-of-annual-meeting-of-stockholders-25ca999f) — Source: Vaxart
- 2026-07-06 20:01 EST — [Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine](https://biopharmsignal.com/news/VXRT/vaxart-reports-topline-12-month-safety-data-from-the-400-participant-sentinel-sa-ad993e0f) — Source: Vaxart
- 2026-07-01 20:00 EST — [Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements](https://biopharmsignal.com/news/VXRT/vaxart-enters-cooperation-agreement-with-stockholder-group-and-announces-board-a-2ed5b0dd) — Source: Vaxart
- 2026-06-26 12:00 EST — [Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY](https://biopharmsignal.com/news/VXRT/vaxart-publishes-presentation-urging-shareholders-to-vote-for-all-six-of-the-com-2bf27563) — Source: Vaxart
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)